欢迎访问行业研究报告数据库

行业分类

当前位置:首页 > 报告详细信息

找到报告 1 篇 当前为第 1 页 共 1

对ERG体内靶向治疗前列腺癌肿瘤的疗效评价

Evaluating the efficacy of ERG targeted therapy in vivo for prostate tumors

作者:Tran, P. T. 作者单位:Johns Hopkins Univ., Baltimore, MD. 加工时间:2014-02-21 信息来源:科技报告(AD) 索取原文[13 页]
关键词:治疗;列腺癌肿瘤
摘 要:The proposed research will examine the suitability of ERG as a target for prostate cancer therapy by using novel modular inducible transgenic mice. Prostate cancer is a large health problem in the United States. Recent efforts to classify distinct molecular subtypes of prostate cancer have shown that >50of prostate cancers possess a chromosomal translocation involving the ERG oncogene. I hypothesized that ERG can serve as an effective molecular therapeutic target for prostate tumors. I planned to show this with novel autochthonous prostate tumor mouse models. During this second year of support we have not been able to been able to adhere to the timeline of our Statement of Work - Task No. 2 - Determine if ERG cooperates with AKT1 for prostate tumorigenesis (months 14-34). We were previously successful at completing the tasks for Task No. 1 - Generate and characterize an inducible ERG prostate specific mouse model (months 1-17), but our characterization of ERG expression from our prostate inducible mouse model did not demonstrate any detectable prostate specific ERG expression at the protein level. Data from another project using the ARR2PB-tTA line has lead us to believe that the level of expression from the ARR2PB-tTA line is low and perhaps insufficient for the in vivo experiments described in our proposal. We are now planning to pursue the Hoxb13-rtTA mouse line allows for much more robust expression of tetO target genes in the mouse 
© 2016 武汉世讯达文化传播有限责任公司 版权所有 技术支持:武汉中网维优
客服中心

QQ咨询


点击这里给我发消息 客服员


电话咨询


027-87841330


微信公众号




展开客服